Pharmacologic Therapy: Novel Approaches for Chronic Obstructive Pulmonary Disease
- 1 October 2007
- journal article
- review article
- Published by Oxford University Press (OUP) in Proceedings of the American Thoracic Society
- Vol. 4 (7) , 543-548
Abstract
Chronic obstructive pulmonary disease (COPD) is increasing in the United States and throughout the world. There have been a number of advances in the treatment of this disease within the last several decades, and these improved therapies continue to become available, making the prospects for the future encouraging. Bronchodilation is the treatment of choice, and we point out in this article the potential availability of many new bronchodilators. There will be several options in the β2-agonist and the anticholinergic categories for once-a-day preparations. There will also be a number of products combining these categories of bronchodilators and inhaled steroids, and the combination products will be available in once-a-day preparations. Also under development are several candidates for specific and effective antiinflammatory agents in COPD. It is likely that our ability to control the inflammation underlying COPD will be a reality in the future. Although many new cases of COPD are being diagnosed in former smokers, for patients who smoke, the most important treatment is smoking cessation. A number of new drugs are available, and more will be brought to market in the future. We have highlighted the details of this important area.Keywords
This publication has 33 references indexed in Scilit:
- Varenicline for Smoking CessationJAMA, 2006
- Effect of Maintenance Therapy With Varenicline on Smoking CessationA Randomized Controlled TrialJAMA, 2006
- Efficacy of Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking CessationA Randomized Controlled TrialJAMA, 2006
- Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking CessationA Randomized Controlled TrialJAMA, 2006
- What to Do With a Patient Who SmokesJAMA, 2005
- In Vivo Efficacy in Airway Disease Models of Roflumilast, a Novel Orally Active PDE4 InhibitorThe Journal of Pharmacology and Experimental Therapeutics, 2001
- Comparison of PDE 4 Inhibitors, Rolipram and SB 207499 (ArifloTM, in a Rat Model of Pulmonary NeutrophiliaPulmonary Pharmacology & Therapeutics, 2001
- The effect of bupropion on nicotine craving and withdrawalPsychopharmacology, 2000
- ArifloTM(SB 207499), a Second Generation Phosphodiesterase 4 Inhibitor for the Treatment of Asthma and COPD: from Concept to ClinicPulmonary Pharmacology & Therapeutics, 1999
- Effects of Smoking Intervention and the Use of an Inhaled Anticholinergic Bronchodilator on the Rate of Decline of FEV1JAMA, 1994